A frequency of somatic mutations in a biological sample (e.g., plasma or serum) of a subject undergoing screening or monitoring for cancer, can be compared with that in the constitutional DNA of the same subject. A parameter can derived from these frequencies and used to determine a ...
除了在现场部署和即时测试(POCT)平台中测量病毒DNA之外,这种快速和高度选择性的传感器可用于评估其他核酸生物标志物。 The significant role of cell-free DNA (cfDNA) for disease diagnosis, including cancer, has garnered a lot of attention. The challenges of creating target-specific primers and the ...
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the monitoring of drug resistance, and for the early detection of cancers. However, the analysis of cfDNA for clinical diagnos...
Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we adapt an enzyme-mediated methylation sequencing method for com...
1月2日《Science》刊登了犹他州大学生物的科研人员的最新研究成果该研究结果公然挑战了科学教科书,第一次证实氨基酸可以在没有DNA和中间模板信使RNA (mRNA)的情况下进行组装。 最新发表文章 01癌症 FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.Smal MP,et al.Exp Oncol...
Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment selection and clinical follow-up of cancer patients. Although its general methodological feasibility and usefulness has been demonstrated, several issues related to standardisation and technical validation must be addr...
Known to be present in the blood of cancer patients for decades, cell-free DNA (cfDNA) is beginning to inform on tumor genetics, tumor burden, and mechanisms of progression and drug resistance. This substrate is amenable for inexpensive noninvasive testing and thus presents a viable approach to...
Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determ...
The analysis of cell-free DNA (cfDNA) as a sensitive biomarker for cancer diagnosis and monitoring has resulted in a need for efficient and standardized cfDNA isolation. In this study, we compared the isolation efficiency of the QIAamp circulating nucleic acid kit (QIA) with four other cfDNA ...
Although traditional cancer detection technologies, such as endoscopy for gastrointestinal cancer, mammography for breast cancer, HPV DNA detection for cervical cancer, and computed tomography and positron emission tomography-computed tomography, are effective, these largely non-invasive screening methods pose...